An executive at Samsung is issued an arrest warrant, as prosecutors in South Korea continue to look into the accounting case leading up the IPO of Samsung BioLogics.
Novartis receives US FDA approval for its gene therapy, Zolgensma, which is a treatment for spinal muscular atrophy, and prices the drug at $2.1m per patient.
Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.
Biogen will halt all clinical trial activity on its Alzheimer’s drug, aducanumab, after its failure in Phase III trials, according to its first quarter financials.
Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.
Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.
After the business was asked by the US FDA to provide more data to secure an approval for its biosimilar, Sandoz decided not to pursue its regulatory filing any further.
South Korea’s SFC has alleged that Samsung BioLogics had intentionally omitted information regarding the joint venture agreement with Biogen that created Samsung Bioepis.
